文献速递其他结缔组织病

基于蛋白和DNA甲基化的评分可作为原发性干燥综合征干扰素系统激活的替代标志物

Protein and DNA methylation-based scores as surrogate markers for interferon system activation in patients with primary Sjögren's syndrome.
PubMed 文献 · RMD Open · 2020-01-01

本研究在原发性干燥综合征(pSS)患者及对照中,评估了利用血浆、血清和DNA样本替代RNA检测干扰素(IFN)系统活性的方法。基于蛋白的IFN评分与mRNA评分相关性良好(r=0.62-0.79),分类一致性79.5%-88.6%,AUC=0.89-0.93;基于DNA甲基化的IFN评分与RNAseq评分强相关(r=0.84),AUC=0.96。这些替代方法在无法获取RNA样本时具有重要价值。

要点

  • 血浆/血清蛋白IFN评分与mRNA评分相关(r=0.62-0.79),可区分患者与对照(AUC=0.89-0.93)。
  • DNA甲基化IFN评分与RNAseq评分强相关(r=0.84),分类患者与对照AUC=0.96。
  • 在无法获取RNA样本的研究中,蛋白或DNA甲基化评分可作为IFN系统激活的替代标志物。

核心结论

  • 血浆、血清或DNA样本可用于评估IFN系统活性,作为RNA检测的替代方法。

研究设计与样本

  • 纳入pSS患者(抗SSA/SSB阳性或阴性)及对照,计算基于蛋白(PD-1、CXCL9、CXCL10)和DNA甲基化(RSAD2、IFIT1、IFI44L)的IFN评分,并与mRNA-based IFN评分(qPCR、Nanostring或RNAseq)比较。

主要发现

  • mRNA-based IFN评分在B细胞与单核细胞间(r=0.93和0.95,p<0.0001)及qPCR与Nanostring间(r=0.92和0.92,p<0.0001)强相关。
  • 血浆和血清pIFN评分在患者中高于对照(p<0.0001),与mRNA-based IFN评分相关(r=0.62-0.79,p<0.0001),彼此相关(r=0.94,p<0.0001)。
  • pIFN评分与mRNA-based IFN评分分类为「高」或「低」IFN特征的一致性为79.5%-88.6%,区分患者与对照的AUC=0.89-0.93(p<0.0001)。
  • DNAm IFN评分与RNAseq IFN评分强相关(r=0.84,p<0.0001),区分患者与对照的AUC=0.96(p<0.0001)。

临床怎么用

  • 在无法获取RNA样本时,可考虑使用血浆/血清蛋白IFN评分或DNA甲基化IFN评分评估pSS患者IFN系统激活状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Standard assessment of interferon (IFN) system activity in systemic rheumatic diseases depends on the availability of RNA samples. In this study, we describe and evaluate alternative methods using plasma, serum and DNA samples, exemplified in the IFN-driven disease primary Sjögren's syndrome (pSS). METHODS: Patients with pSS seropositive or negative for anti-SSA/SSB and controls were included. Protein-based IFN (pIFN) scores were calculated from levels of PD-1, CXCL9 and CXCL10. DNA methylation-based (DNAm) IFN scores were calculated from DNAm levels at RSAD2, IFIT1 and IFI44L. Scores were compared with mRNA-based IFN scores measured by quantitative PCR (qPCR), Nanostring or RNA sequencing (RNAseq). RESULTS: mRNA-based IFN scores displayed strong correlations between B cells and monocytes (r=0.93 and 0.95, p<0.0001) and between qPCR and Nanostring measurements (r=0.92 and 0.92, p<0.0001). The pIFN score in plasma and serum was higher in patients compared with controls (p<0.0001) and correlated well with mRNA-based IFN scores (r=0.62-0.79, p<0.0001), as well as with each other (r=0.94, p<0.0001). Concordance of classification as 'high' or 'low' IFN signature between the pIFN score and mRNA-based IFN scores ranged from 79.5% to 88.6%, and the pIFN score was effective at classifying patients and controls (area under the curve, AUC=0.89-0.93, p<0.0001). The DNAm IFN score showed strong correlation to the RNAseq IFN score (r=0.84, p<0.0001) and performed well in classifying patients and controls (AUC=0.96, p<0.0001). CONCLUSIONS: We describe novel methods of assessing IFN system activity in plasma, serum or DNA samples, which may prove particularly valuable in studies where RNA samples are not available.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Björk A, Richardsdotter Andersson E, Imgenberg-Kreuz J, et al. Protein and DNA methylation-based scores as surrogate markers for interferon system activation in patients with primary Sjögren's syndrome. RMD Open. 2020. PMID: 31958277. doi:10.1136/rmdopen-2019-000995

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。